nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—ADRB1—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.063	0.0675	CbGpPWpGaD
Salbutamol—ADRB2—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.0617	0.066	CbGpPWpGaD
Salbutamol—ADRB1—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0331	0.0355	CbGpPWpGaD
Salbutamol—ADRB2—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0324	0.0347	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0223	0.0239	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0218	0.0234	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0218	0.0234	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0214	0.0229	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0187	0.0201	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0184	0.0197	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0183	0.0196	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.018	0.0192	CbGpPWpGaD
Salbutamol—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.0174	0.262	CrCbGaD
Salbutamol—ADRB1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0132	0.0142	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0129	0.0139	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0127	0.0136	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0124	0.0133	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0123	0.0132	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.012	0.0129	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0119	0.0128	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0117	0.0125	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0117	0.0125	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0116	0.0124	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0115	0.0123	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0113	0.0121	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0111	0.0119	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0109	0.0117	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0108	0.0115	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0105	0.0113	CbGpPWpGaD
Salbutamol—Norepinephrine—ADRA2C—attention deficit hyperactivity disorder	0.0103	0.155	CrCbGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0103	0.0111	CbGpPWpGaD
Salbutamol—ADRB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0103	0.011	CbGpPWpGaD
Salbutamol—Phenylephrine—MAOA—attention deficit hyperactivity disorder	0.0102	0.153	CrCbGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0101	0.0108	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.01	0.0107	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00984	0.0105	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0098	0.0105	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00972	0.0104	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00963	0.0103	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00951	0.0102	CbGpPWpGaD
Salbutamol—Epinephrine—ADRA2C—attention deficit hyperactivity disorder	0.00938	0.141	CrCbGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00906	0.0097	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00886	0.00949	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00757	0.00811	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00755	0.00808	CbGpPWpGaD
Salbutamol—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.00744	0.112	CrCbGaD
Salbutamol—ADRB2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00741	0.00794	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00738	0.00791	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00634	0.00679	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0062	0.00665	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00518	0.00554	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00502	0.00538	CbGpPWpGaD
Salbutamol—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00485	0.00519	CbGpPWpGaD
Salbutamol—Norepinephrine—ADRA2A—attention deficit hyperactivity disorder	0.00441	0.0663	CrCbGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0043	0.00461	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00427	0.00457	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00421	0.00451	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00421	0.00451	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00421	0.00451	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00418	0.00448	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00417	0.00447	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00412	0.00442	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00412	0.00442	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00409	0.00438	CbGpPWpGaD
Salbutamol—Epinephrine—ADRA2A—attention deficit hyperactivity disorder	0.004	0.0602	CrCbGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00369	0.00395	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00361	0.00387	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00361	0.00386	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00353	0.00378	CbGpPWpGaD
Salbutamol—Norepinephrine—DRD2—attention deficit hyperactivity disorder	0.00335	0.0503	CrCbGaD
Salbutamol—ADRB2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00328	0.00351	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00292	0.00313	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00286	0.00306	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00281	0.00301	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00275	0.00295	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00275	0.00294	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00269	0.00288	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00255	0.00274	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0025	0.00268	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0025	0.00268	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00245	0.00262	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00237	0.00254	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00236	0.00253	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00232	0.00249	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00231	0.00248	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.0023	0.00246	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00226	0.00242	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00225	0.00241	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00223	0.00239	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00221	0.00237	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00219	0.00234	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00218	0.00234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00215	0.0023	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00214	0.00229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0021	0.00225	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00208	0.00223	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00203	0.00218	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00203	0.00218	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00199	0.00213	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00197	0.00211	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00194	0.00207	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00193	0.00206	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00191	0.00205	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00191	0.00204	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00189	0.00203	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00187	0.002	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00186	0.002	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00178	0.00191	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00174	0.00187	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00167	0.00178	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00163	0.00175	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00159	0.0017	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00155	0.00166	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00155	0.00166	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00155	0.00166	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00152	0.00163	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00151	0.00162	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0015	0.00161	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00149	0.0016	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00147	0.00158	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00147	0.00157	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00146	0.00156	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00146	0.00156	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00154	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00144	0.00154	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00142	0.00153	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00142	0.00153	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00141	0.00151	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00141	0.00151	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00138	0.00148	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00136	0.00145	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00133	0.00142	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00127	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00125	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00124	0.00133	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00122	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00108	0.00115	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00105	0.00113	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00099	0.00106	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000978	0.00105	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000969	0.00104	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000957	0.00102	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00095	0.00102	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000941	0.00101	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000929	0.000996	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000921	0.000986	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000875	0.000938	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000856	0.000917	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000855	0.000916	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000851	0.000911	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000848	0.000908	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000836	0.000896	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000834	0.000893	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000833	0.000892	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000832	0.000892	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000829	0.000888	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000823	0.000881	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000817	0.000876	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000815	0.000873	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000815	0.000873	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000805	0.000862	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.0008	0.000857	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000797	0.000854	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000795	0.000851	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000791	0.000848	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000786	0.000842	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000777	0.000833	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00077	0.000825	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000767	0.000821	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000757	0.00081	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000753	0.000807	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00075	0.000803	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000747	0.0008	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00074	0.000793	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000731	0.000783	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000696	0.000746	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000681	0.000729	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000578	0.000619	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000565	0.000605	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000537	0.000575	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000525	0.000563	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000505	0.000541	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000494	0.000529	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000488	0.000522	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000477	0.000511	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000469	0.000503	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000459	0.000492	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000455	0.000487	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000447	0.000479	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000445	0.000476	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000441	0.000473	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000437	0.000468	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000432	0.000463	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000411	0.000441	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000402	0.000431	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000326	0.000349	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000288	0.000309	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000282	0.000302	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000225	0.000241	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000225	0.000241	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000221	0.000237	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000206	0.00022	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00018	0.000193	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000171	0.000183	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000153	0.000163	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000149	0.00016	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000136	0.000146	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000135	0.000145	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.84e-05	6.26e-05	CbGpPWpGaD
